Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits. The poster presentation highlights data in primary human hepatocytes demonstrating the high specificity and lack of detectable off-target editing for PBGENE-HBV at therapeutically relevant doses. The poster will also showcase non-human primate data demonstrating good tolerability of a multi-dosing approach for the treatment of chronic hepatitis B.
Precision BioSciences, Inc.（纳斯达克股票代码：DTIL）是一家利用其新型专有ARCUS平台开发活体基因编辑疗法的先进基因编辑公司。该公司今天宣布，该公司将在欧洲肝脏研究协会（EASL）上提供其PBGENE-HBV临床候选药物的临床前数据，重点介绍ARCUS进行高效、持久和有针对性的消除编辑的差异化能力。海报展示重点介绍了原代人类肝细胞中的数据，这些数据表明 PBGENE-HBV 在治疗相关剂量下具有很高的特异性且缺乏可检测的脱靶编辑。海报还将展示非人类灵长类动物的数据，这些数据表明多剂量治疗慢性乙型肝炎的方法具有良好的耐受性。